Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Equities researchers at Stifel Nicolaus initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR - Get Free Report) in a report issued on Wednesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $50.00 price target on the stock. Stifel Nicolaus' price target indicates a potential upside of 84.91% from the company's current price.

GPCR has been the topic of a number of other research reports. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reiterated a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an "overweight" rating and a $118.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Trading Down 0.5 %

NASDAQ GPCR traded down $0.14 during mid-day trading on Wednesday, reaching $27.04. 837,138 shares of the company's stock traded hands, compared to its average volume of 578,436. Structure Therapeutics has a 1-year low of $25.90 and a 1-year high of $62.74. The company has a fifty day simple moving average of $32.85 and a 200-day simple moving average of $36.77. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -36.54 and a beta of -2.78.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GPCR. GAMMA Investing LLC increased its position in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares during the period. JPMorgan Chase & Co. lifted its holdings in Structure Therapeutics by 302.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock valued at $1,489,000 after acquiring an additional 25,500 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock valued at $23,936,000 after purchasing an additional 380,115 shares in the last quarter. Exome Asset Management LLC acquired a new position in Structure Therapeutics in the third quarter worth approximately $5,274,000. Finally, Franklin Resources Inc. boosted its stake in shares of Structure Therapeutics by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock worth $30,991,000 after acquiring an additional 60,397 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.